# Clinical investigation – application form under Medical Device Regulation.

**Application form** version 1.0

Section 1: Clinical investigation identification				
1.1 Sponsor identification				
Name:				
	Street name:	Street number:		
Address	Postal code:	City:		
	Country:			
Telephone number:				
Email:				
Contact person of the sponsor				
First name:				
Last name:				
Telephone number:				
Email:				

# Sponsor's legal representative identification

Do you have a leg	gal representative?		
Yes	No		
		legal representative (section 1.2)	
1.2 Legal represent	tative identification		
Organisation nan	ne:		
	Street name:	Street number:	
Address	Postal code:	City:	
	Country:	<b>'</b>	
Telephone numb	er:		
Email:			
Contact pe	rson of the legal representat	<u>tive</u>	
First name:			
Last name:			
Telephone number	:		
Email:			

# $\underline{\textbf{Contact person for the clinical investigation}}$

Same as contact person of sponsor Same as contact

clinical investigation.

Other

person of legal representative

Other contact person for the clinical investigation				
First name:				
Last name:				
	Street name:	Street number:		
Address	Postal code:	City:		
	Country:			

If you selected other, please fill in the section below related to the other contact person for this

# 1.3 Clinical investigation type

Select the appropriate regulatory pathway for the application :

Clinical investigation application (MDR Art. 62(1)/IVDR Art. 58(1))			
PMCF investigation notification (MDR Art. 74(1))			
Other clinical investigation application/notification - national application (MDR Art. 82(1))			
1.4 Submission type			
First submission in the EEA			
First submission at the national level (clinical investigation has been already submitted in EEA)			
In this case, please provide the clinical investigation ID (CIV-ID) provided			
Resubmission			
Please provide the CIV-ID if already available			
1.5 Participating countries within the EU/EEA/UK (Northern Ireland), Turkey and Switzerland			
Select the participating countries for the clinical investigation			

# 1.6 Participating countries outside EU/EEA/UK

If this study is part of a multi-site clinical investigation outside the EU/EEA/UK, please provide a list of all the non EU/EEA countries the study plans to be carried out in.
an the new 20, 22, too and too are start, plant of a control of
1.7 Clinical investigation plan (CIP)
CIP code:
CIP version:
CIP date:
1.8 Clinical investigation title
Full title:
Short title:
Title for lay people:

#### **Section 2: Clinical investigation description**

#### 2.1 Scientific opinion

Has the manufacturer consulted with an expert panel as outlined in Art. 61(2) of Regulation (EU) 2017/745.

Y Yes No

.

#### 2.2 Design of the clinical investigation

Exploratory investigation Confirmatory investigation

Observational investigation

First in human Not first in human investigation

#### 2.3 Design methodology

Case Contro Controlled Cross-sectional Double blind

Parallel Randomised Open

Other:

#### 2.4 Development stage

Pilot stage Pivotal stage Post-market stage

# 2.5 Objectives and endpoints

Primary objective(s):
Timary objective(s).
Secondary objective(s):
Other objective(s):
other objective(s).
Primary endpoint(s):

Secondary endpoint(s):	
Other endpoint(s):	
Other enapolitis):	
2.6 Synopsis of the clinical investigation	
Overall synopsis:	

# 2.7 Planned number of subjects

In Europe:		
In Asia:		
In Africa:		
In North Am	erica:	
In South Amo	erica:	
In Oceania:		
Total planne	ed number of su	hiosts
тосат ріанне	a number of su	ujecus.
2.8 Dura	tion of clinical	l investigation
Estimated	start date:	
Estimated	end date:	
2.9 <b>P</b> op	oulation	
_		
2.	.9.1 Medical co	adition ————————————————————————————————————
Is there an	associated med	dical condition?
Yes	No	
Is the med	ical condition co	onsidered to be rare?
Yes	No	
	2.9.2 Therapeu	utic area
Coloct the		
Select the	: trierapeutic a	rea that the clinical investigation falls under
	2.9.3 Gender o	f subjects
Female	e Male	Other
1		

2.9.4 Inclusion criteria	
2.9.5 Exclusion criteria	

## $\pmb{2.9.6}$ Type of subjects that the clinical investigation plans to recruit

Healthy	<b>Patients</b>	Vulnerable population	Incapacited subjects
Minors	Pregnant women	Breastfeeding women	Patients in emergency situations
Other (plea	se specify)		

## $\pmb{2.9.7}$ Age range of the participants that the clinical investigation plans to include

In utero	Adults (from 18 to 84 years)
Newborns (from 0 to 27 days)	Elderly (from 85 years)
Infants and toddlers (from 28 days to 23 months)	
Children (from 2 to 5 years)	
Adolescents (from 12 to 17 years)	

# 2.10 Scope of the investigational device

# ${\bf 2.10.1\ Combined\ investigation\ Medical\ Device/In\ Vitro\ Diagnostic?}$

Yes No		
If yes, please provi	de the related IVD performance st	udy identification number
2.10.2 is products?	the application submitted in paralle	l with an application for a clinical trial on medicinal
Yes No		
If yes, please provide	the EU Clinical Trial Number:	
2.11 Coordina	ting investigator	
First name:		
Last name:		
	Street name:	Street number:
Address	Postal code:	City:
	Country:	
Telephone numbe	r:	•
Email:		

# **Section 3: Investigational device(s)**

#### 3.1 Investigational medical device

#### 3.1.1 Device purposes

#### 3.1.2 Device type

Implantable	System
-------------	--------

Active device Non-medical purpose

Measuring function Sterile

Reusable surgical instrument Software

Intended to administer or remove medicinal

substance

#### 3.1.3 Invasiness

ls it an invas	ive medical de	evice?			
Yes	No				

#### 3.1.4 Device Identifiers

Generic denomination:
Device trade name: Model:
Device name:
Device name.
European Medical Device nomenclature
Medical device classification:
Classification rule:
Device description:
Intended (clinical) purpose:
Does the device contain or incorporate medicinal substance(s)?
boes the device contain of incorporate medicinal substance(s):
Yes No
If yes, please provide the medicinal substance(s) name(s):
The device incorporates, as an integral part, or it is manufactured using:
Non-viable tissues of human origin or their derivatives with an ancillary action
Non-viable cells of human origin or their derivatives with an ancillary action
Non-viable tissues of animal origin or their derivatives with an ancillary action Non-viable cells of animal origin or their derivatives with an ancillary action
Non-viable biological substance other than those referred to in the previous points
None of these proposals/Not applicable

is the inves	stigational Device CE marked?
Yes	No
<u>If yes</u> , pleas	se provide the information in the box below.
To what exte	ent is the intended purpose of the device in the clinical investigation covered by the CE-mark?
CE 1	marked device will be used outside the scope of its CE mark
	marked device will be used within the scope of its CE mark and no additional procedures are eseen in the clinical investigation
	marked device will used within the scope of its CE mark, but additional procedures are foreseen in clinical investigation
	Are those additional procedures considered to be burdensome and/or invasive?
	Yes No
	Please, comment why do you consider as such?
Information	related to the Notified body involved, if applicable:
Not	tified body number:
Not	ified body name:
3.2 Prev	vious clinical investigation
Has this de	vice been investigated in a clinical investigation within the EU previously?
Yes	No
If yes, pleas clinical inve	se provide the relevant reference number(s) (such as SIN, CIV-ID, other reference(s)) of the previous estigations
3.3 Scie	ntific opinion/view
Has the inv	restigational/study device been subject to a national scientific view/opinion from an Expert Panel
Yes	No
3.4 Man	nufacturer of the investigational device
Is the manu	ufacturer the same as the sponsor?
Yes	No
If no, please	e fill in the requested information in section 3.4.1 and 3.4.2.

#### 3.4.1 Manufacturer information

Organisation nam	ne:		
	Street name:	Street number:	
Address	Postal code:	City:	
	Country:	<u> </u>	
Telephone numb	er:		
Email:			
Contact p	erson of the manufacturer		
First name:			
Last name:			
Telephone number	:		
Email:			
	orised representativ		
Organisation nam	ne:		
	Street name:	Street number:	
Address	Postal code:	City:	
	Country:		
Telephone numb	er:		
Email:			
Contact p	erson of the authorised re	presentative	
First name:			
Last name:			
Telephone number	•		
Email:			

Additional devices could be added by using a duplicated section 3, in appendix to this application form.

# **Section 4: Comparator**

## 4.1 Applicability of section 4

Is there a comparator included in the clinical investigation	ition?.		
Yes No			
If yes, the section from 4.2 needs to be completed.			
4.2 Type of comparator			
Therapy			
Placebo			
No treatment			
Medical device			
4.2.1 Medical device as comparator			
Is the comparator medical device CE marked?	Yes	No	
If yes, will the CE marked comparator medical device	be used in t	the clinical invest	igation within the
scope of its CE mark? Yes No			
Generic denomination:			
Device trade name:	Mod	el:	
Device name:			
European Medical Device Nomenclature :			
Medical device classification:			
Device description:			

Intended (clinical) purpose:
`
Does the comparator device contain or incorporate medicinal substance(s)?
<del></del>
Yes No
165 110
If yes, please provide the medicinal substance(s) name(s):
mi
The comparator device incorporates, as an integral part, or it is manufactured using:
Non-violal tiesues of human origin on their derivetives with an engillary estion
Non-viable tissues of human origin or their derivatives with an ancillary action
Non-viable cells of human origin or their derivatives with an ancillary action Non-viable tissues of animal origin or their derivatives with an ancillary action
v
Non-viable cells of animal origin or their derivatives with an ancillary action Non-viable biological substance other than those referred to in the previous points
•
None of these proposals/Not applicable

Additional comparators could be added by using a duplicated section 4, in appendix to this application form

#### **Section 5: National information**

#### 5.1 Study site information

Please provide the list of sites taking part in the clinical investigation

Name of institution	Site address	Investigator attached to this site	Contact information of investigators

Additional sites could be added by using a duplicated section 5.1, in appendix to this application form

# **5.2 Ethics committee information**

Select the applical	ble option:	
Ethics com	mittee opinion available	
Ethics com	mittee opinion under review	
Ethics com	mittee opinion is not mandatory before su	ubmission to the competent authority
	nittee has to be selected by the sponsor information's below.	before submission, please provide the
Organisation nam	ne:	
	Street name:	Street number:
Address	Postal code:	City:
	Country:	
Telephone numb	er:	
Email:		

# 5.3 Status of the clinical investigation

Is the sponsor con	idered as commercial according to national legislation?	
Yes	No	
5.4 Expected number of subjects recruited within the Member State		
How many subjects applying to?	are expected to be recruited into the study in the Member State you are	
•	rtify that the information and documentation submitted with this notification is corre I and all the information requested has been supplied. The investigated (medical) devi	
	lies with the applicable general safety and performance requirements, apart from tho estigation and that every precaution has been taken to protect the health and safety of patient and/or user.	
I confirm th	t all the clinical investigations information collected for this application, has been done in compliance with the European data protection legislation (GDPR).	
Name:		
Position:		